Boston Scientific recalls ICDs, CRT-Ds
This article was originally published in The Silver Sheet
Executive Summary
Boston Scientific is recalling all of its implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) because it made manufacturing process changes without proper FDA approval. The firm said March 15 that it will stop shipments and retrieve all field inventory of its ICDs and CRT-Ds, including the Cognis, Teligen, Confient, Livian, Prizm, Renewal and Vitality product lines. Boston Scientific said it learned of two unapproved manufacturing process changes during a "planned process review." The changes were validated but not submitted to FDA, the company said. Such changes, if material to the safety or effectiveness of the product, require PMA-supplement approval. The firm is acting "voluntarily and expeditiously" to resolve the issue and has seen "no evidence of any risk to patient safety," CEO Ray Elliott said. The company is not recommending explantation of already implanted devices, and its pacemakers and other products are not affected by the advisory
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.